The role of transforming growth factor β1 in the regulation of blood pressure

Current Hypertension Reviews

Volumn 10, Issue 4, 2015, Pages 223-238

  Matsuki, Kota ^a   Hathaway, Catherine K ^a   Lawrence, Marlon G ^a   Smithies, Oliver ^a   Kakoki, Masao ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Collecting duct; Corticosteroid; Endothelin; Epithelial sodium channel; Nitric oxide

Indexed keywords

ENDOTHELIN 1; NITRIC OXIDE; TRANSFORMING GROWTH FACTOR BETA1; CORTICOSTEROID; ELECTROLYTE; SODIUM;

ARTICLE; BLOOD PRESSURE REGULATION; HUMAN; HYPERTENSION; NONHUMAN; PLASMA VOLUME; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SODIUM ABSORPTION; SODIUM INTAKE; SODIUM TRANSPORT; URINARY EXCRETION; ANIMAL; BLOOD PRESSURE; HYPERALDOSTERONISM; METABOLISM; MOUSE; PHYSIOLOGY; URINE;

ADRENAL CORTEX HORMONES; ANIMALS; BLOOD PRESSURE; ELECTROLYTES; ENDOTHELIN-1; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MICE; NITRIC OXIDE; PLASMA VOLUME; RENIN-ANGIOTENSIN SYSTEM; SODIUM; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84928945234     PISSN: 15734021     EISSN: 18756506     Source Type: Journal    
DOI: 10.2174/157340211004150319123313     Document Type: Article

References (192)

1. [1. Munoz-Espin D, Canamero M, Maraver A, et al. Programmed cell senescence during mammalian embryonic development. Cell 2013; 155(5): 1104-18.
2. Barcellos-Hoff MH, Cucinotta FA. New tricks for an old fox: Impact of TGFbeta on the DNA damage response and genomic stability. Sci Signal 2014; 7(341): re5.
3. Wiener Z, Band AM, Kallio P, et al. Oncogenic mutations in intestinal adenomas regulate Bim-mediated apoptosis induced by TGF-beta. Proc Natl Acad Sci U S A 2014; 111(21): E2229-36.
4. Han A, Zhao H, Li J, Pelikan R, Chai Y. ALK5-mediated transforming growth factor beta signaling in neural crest cells controls craniofacial muscle development via tissue-tissue interactions. Mol Cell Biol 2014; 34(16): 3120-31.
5. Feng YF, Yuan F, Guo H, Wu WZ. TGF-beta1 enhances SDF-1- induced migration and tube formation of choroid-retinal endothelial cells by up-regulating CXCR4 and CXCR7 expression. Mol Cell Biochem 2014; 397(1-2): 131-8.
6. Stephen TL, Rutkowski MR, Allegrezza MJ, et al. Transforming Growth Factor beta-Mediated Suppression of Antitumor T Cells Requires FoxP1 Transcription Factor Expression. Immunity 2014; 41(3): 427-39.
7. Grafe I, Yang T, Alexander S, et al. Excessive transforming growth factor-beta signaling is a common mechanism in osteogenesis imperfecta. Nat Med 2014; 20(6): 670-5.
8. Park JG, Lee DH, Moon YS, Kim KH. Reversine increases the plasticity of lineage-committed preadipocytes to osteogenesis by inhibiting adipogenesis through induction of TGF-beta pathway in vitro. Biochem Biophys Res Commun 2014; 446(1): 30-6.
9. Wang YW, Liou NH, Cherng JH, et al. siRNA-Targeting Transforming Growth Factor-beta Type I Receptor Reduces Wound Scarring and Extracellular Matrix Deposition of Scar Tissue. J Invest Dermatol 2014; 134(7): 2016-25.
10. Akhurst RJ, Hata A. Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov 2012; 11(10): 790-811.
11. Clouthier DE, Comerford SA, Hammer RE. Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCKTGF- beta1 transgenic mice. J Clin Invest 1997; 100(11): 2697-713.
12. Sanderson N, Factor V, Nagy P, et al. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A 1995; 92(7): 2572-6.
13. Roberts AB, Heine UI, Flanders KC, Sporn MB. Transforming growth factor-beta. Major role in regulation of extracellular matrix. Ann N Y Acad Sci 1990; 580: 225-32.
14. Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGFbeta1- induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003; 9(7): 964-8.
15. Wylie-Sears J, Levine RA, Bischoff J. Losartan inhibits endothelial-to-mesenchymal transformation in mitral valve endothelial cells by blocking transforming growth factor-betainduced phosphorylation of ERK. Biochem Biophys Res Commun 2014; 446(4): 870-5.
16. Saito S, Shimizu H, Yisireyili M, Nishijima F, Enomoto A, Niwa T. Indoxyl sulfate-induced activation of (pro)renin receptor is involved in expression of TGF-beta1 and alpha-smooth muscle actin in proximal tubular cells. Endocrinology 2014; 155(5): 1899-907.
17. Saraswat MS, Addepalli V, Jain M, Pawar VD, Patel RB. Renoprotective activity of aliskiren, a renin inhibitor in cyclosporine A induced hypertensive nephropathy in dTG mice. Pharmacol Rep 2014; 66(1): 62-7.
18. Bae EH, Kim IJ, Joo SY, et al. Renoprotective effects of the direct renin inhibitor aliskiren on gentamicin-induced nephrotoxicity in rats. J Renin Angiotensin Aldosterone Syst 2014; 15(4): 348-61.
19. Gallo EM, Loch DC, Habashi JP, et al. Angiotensin II-dependent TGF-beta signaling contributes to Loeys-Dietz syndrome vascular pathogenesis. J Clin Invest 2014; 124(1): 448-60.
20. Zhang Y, Shao L, Ma A, et al. Telmisartan delays myocardial fibrosis in rats with hypertensive left ventricular hypertrophy by TGF-beta1/Smad signal pathway. Hypertens Res 2014; 37(1): 43-9.
21. Hotta M, Baird A. Differential effects of transforming growth factor type beta on the growth and function of adrenocortical cells in vitro. Proc Natl Acad Sci U S A 1986; 83(20): 7795-9.
22. Liakos P, Lenz D, Bernhardt R, Feige JJ, Defaye G. Transforming growth factor beta1 inhibits aldosterone and cortisol production in the human adrenocortical cell line NCI-H295R through inhibition of CYP11B1 and CYP11B2 expression. J Endocrinol 2003; 176(1): 69-82.
23. Gupta P, Franco-Saenz R, Gentry LE, Mulrow PJ. Transforming growth factor-beta 1 inhibits aldosterone and stimulates adrenal renin in cultured bovine zona glomerulosa cells. Endocrinology 1992; 131(2): 631-6.
24. Kakoki M, Pochynyuk OM, Hathaway CM, et al. Primary aldosteronism and impaired natriuresis in mice underexpressing TGFbeta1. Proc Natl Acad Sci U S A 2013; 110(14): 5600-5.
25. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390(6659): 465-71.
26. Pardali E, Ten Dijke P. TGFbeta signaling and cardiovascular diseases. Int J Biol Sci 2012; 8(2): 195-213.
27. ten Dijke P, Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007; 8(11): 857-69.
28. Wrana JL, Attisano L, Carcamo J, et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell 1992; 71(6): 1003-14.
29. Akhurst RJ, Hata A. Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov 2012; 11(10): 790-811.
30. Guo X, Wang XF. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res 2009; 19(1): 71-88.
31. Suthanthiran M, Li B, Song JO, et al. Transforming growth factorbeta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci U S A 2000; 97(7): 3479-84.
32. Rostand SG, Brown G, Kirk KA, Rutsky EA, Dustan HP. Renal insufficiency in treated essential hypertension. N Engl J Med 1989; 320(11): 684-8.
33. Laviades C, Varo N, Diez J. Transforming growth factor beta in hypertensives with cardiorenal damage. Hypertension 2000; 36(4): 517-22.
34. Cambien F, Ricard S, Troesch A, et al. Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study. Hypertension 1996; 28(5): 881-7.
35. Li B, Khanna A, Sharma V, Singh T, Suthanthiran M, August P. TGF-beta1 DNA polymorphisms, protein levels, and blood pressure. Hypertension 1999; 33(1 Pt 2): 271-5.
36. Niu W. Evaluation of Transforming Growth Factor Beta-1 Gene 869T/C Polymorphism with Hypertension: A Meta-Analysis. Int J Hypertens 2011; 2011: 934265.
37. Yan-Yan L. Transforming growth factor beta1 +869T/C gene polymorphism and essential hypertension: a meta-analysis involving 2708 participants in the Chinese population. Intern Med 2011; 50(10): 1089-92.
38. Lavoie P, Robitaille G, Agharazii M, Ledbetter S, Lebel M, Lariviere R. Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats. J Hypertens 2005; 23(10): 1895-903.
39. Zacchigna L, Vecchione C, Notte A, et al. Emilin1 links TGF-beta maturation to blood pressure homeostasis. Cell 2006; 124(5): 929-42.
40. Badri KR, Yue M, Carretero OA, et al. Blood pressure homeostasis is maintained by a P311-TGF-beta axis. J Clin Invest 2013; 123(10): 4502-12.
41. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12(6): 642-9.
42. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992; 359(6397): 693-9.
43. Kulkarni AB, Huh CG, Becker D, et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A 1993; 90(2): 770-4.
44. Letterio JJ, Geiser AG, Kulkarni AB, Roche NS, Sporn MB, Roberts AB. Maternal rescue of transforming growth factor-beta 1 null mice. Science 1994; 264(5167): 1936-8.
45. Schultz Jel J, Witt SA, Glascock BJ, et al. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 2002; 109(6): 787-96.
46. Guzik TJ, Hoch NE, Brown KA, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007; 204(10): 2449-60.
47. Kakoki M, Tsai YS, Kim HS, et al. Altering the expression in mice of genes by modifying their 3' regions. Dev Cell 2004; 6(4): 597-606.
48. Shaw G, Kamen R. A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986; 46(5): 659-67.
49. Ando T, Okuda S, Tamaki K, Yoshitomi K, Fujishima M. Localization of transforming growth factor-beta and latent transforming growth factor-beta binding protein in rat kidney. Kidney Int 1995; 47(3): 733-9.
50. Banas MC, Parks WT, Hudkins KL, et al. Localization of TGFbeta signaling intermediates Smad2, 3, 4, and 7 in developing and mature human and mouse kidney. J Histochem Cytochem 2007; 55(3): 275-85.
51. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98(1): 121-8.
52. Carvalho JJ, Baruzzi RG, Howard PF, et al. Blood pressure in four remote populations in the INTERSALT Study. Hypertension 1989; 14(3): 238-46.
53. Mancilha-Carvalho JJ, de Oliveira R, Esposito RJ. Blood pressure and electrolyte excretion in the Yanomamo Indians, an isolated population. J Hum Hypertens 1989; 3(5): 309-14.
54. Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. BMJ 1988; 297(6644): 319-28.
55. Guyton AC. Blood pressure control--special role of the kidneys and body fluids. Science 1991; 252(5014): 1813-6.
56. Guyton AC. The surprising kidney-fluid mechanism for pressure control--its infinite gain! Hypertension 1990; 16(6): 725-30.
57. Rossier BC. Negative regulators of sodium transport in the kidney: key factors in understanding salt-sensitive hypertension? J Clin Invest 2003; 111(7): 947-50.
58. Kanbay M, Chen Y, Solak Y, Sanders PW. Mechanisms and consequences of salt sensitivity and dietary salt intake. Curr Opin Nephrol Hypertens 2011; 20(1): 37-43.
59. Fujita T. Mechanism of salt-sensitive hypertension: focus on adrenal and sympathetic nervous systems. J Am Soc Nephrol 2014; 25(6): 1148-55.
60. Garty H, Palmer LG. Epithelial sodium channels: function, structure, and regulation. Physiol Rev 1997; 77(2): 359-96.
61. Loffing J, Korbmacher C. Regulated sodium transport in the renal connecting tubule (CNT) via the epithelial sodium channel (ENaC). Pflugers Arch 2009; 458(1): 111-35.
62. Mamenko M, Zaika O, Doris PA, Pochynyuk O. Salt-dependent inhibition of epithelial Na+ channel-mediated sodium reabsorption in the aldosterone-sensitive distal nephron by bradykinin. Hypertension 2012; 60(5): 1234-41.
63. Mamenko M, Zaika O, Ilatovskaya DV, Staruschenko A, Pochynyuk O. Angiotensin II Increases Activity of the Epithelial Na+ Channel (ENaC) in Distal Nephron Additively to Aldosterone. J Biol Chem 2012; 287(1): 660-71.
64. Helms MN, Yu L, Malik B, Kleinhenz DJ, Hart CM, Eaton DC. Role of SGK1 in nitric oxide inhibition of ENaC in Na+- transporting epithelia. Am J Physiol Cell Physiol 2005; 289(3): C717-26.
65. Pochynyuk O, Bugaj V, Vandewalle A, Stockand JD. Purinergic control of apical plasma membrane PI(4,5)P2 levels sets ENaC activity in principal cells. Am J Physiol Renal Physiol 2008; 294(1): F38-46.
66. Bugaj V, Pochynyuk O, Stockand JD. Activation of the epithelial Na+ channel in the collecting duct by vasopressin contributes to water reabsorption. Am J Physiol Renal Physiol 2009; 297(5): F1411-8.
67. Staruschenko A, Pochynyuk O, Vandewalle A, Bugaj V, Stockand JD. Acute regulation of the epithelial Na+ channel by phosphatidylinositide 3-OH kinase signaling in native collecting duct principal cells. J Am Soc Nephrol 2007; 18(6): 1652-61.
68. Wegmann M, Nusing RM. Prostaglandin E2 stimulates sodium reabsorption in MDCK C7 cells, a renal collecting duct principal cell model. Prostaglandins Leukot Essent Fatty Acids 2003; 69(5): 315-22.
69. Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005; 11(8): 861-6.
70. Kashlan OB, Kleyman TR. ENaC structure and function in the wake of a resolved structure of a family member. Am J Physiol Renal Physiol 2011; 301(4): F684-96.
71. Shimkets RA, Warnock DG, Bositis CM, et al. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 1994; 79(3): 407-14.
72. Chang SS, Grunder S, Hanukoglu A, et al. Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nat Genet 1996; 12(3): 248-53.
73. Hummler E, Barker P, Gatzy J, et al. Early death due to defective neonatal lung liquid clearance in alpha-ENaC-deficient mice. Nat Genet 1996; 12(3): 325-28.
74. McDonald FJ, Yang B, Hrstka RF, et al. Disruption of the beta subunit of the epithelial Na+ channel in mice: hyperkalemia and neonatal death associated with a pseudohypoaldosteronism phenotype. Proc Natl Acad Sci U S A 1999; 96(4): 1727-31.
75. Barker PM, Nguyen MS, Gatzy JT, et al. Role of gammaENaC subunit in lung liquid clearance and electrolyte balance in newborn mice. Insights into perinatal adaptation and pseudohypoaldosteronism. J Clin Invest 1998; 102(8): 1634-40.
76. Rubera I, Loffing J, Palmer LG, et al. Collecting duct-specific gene inactivation of alphaENaC in the mouse kidney does not impair sodium and potassium balance. J Clin Invest 2003; 112(4): 554-65.
77. Wilson FH, Disse-Nicodeme S, Choate KA, et al. Human hypertension caused by mutations in WNK kinases. Science 2001; 293(5532): 1107-12.
78. Yang CL, Angell J, Mitchell R, Ellison DH. WNK kinases regulate thiazide-sensitive Na-Cl cotransport. J Clin Invest 2003; 111(7): 1039-45.
79. Mu S, Shimosawa T, Ogura S, et al. Epigenetic modulation of the renal beta-adrenergic-WNK4 pathway in salt-sensitive hypertension. Nat Med 2011; 17(5): 573-80.
80. Simon DB, Nelson-Williams C, Bia MJ, et al. Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet 1996; 12(1): 24-30.
81. Gross O, Girgert R, Rubel D, Temme J, Theissen S, Muller GA. Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fibrosis. Am J Hypertens 2011; 24(3): 355-61.
82. Feldman DL, Jin L, Xuan H, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008; 52(1): 130-6.
83. Chua CC, Diglio CA, Siu BB, Chua BH. Angiotensin II induces TGF-beta 1 production in rat heart endothelial cells. Biochim Biophys Acta 1994; 1223(1): 141-7.
84. Wolf G, Ziyadeh FN, Stahl RA. Angiotensin II stimulates expression of transforming growth factor beta receptor type II in cultured mouse proximal tubular cells. J Mol Med (Berl) 1999; 77(7): 556-64.
85. Ruiz-Ortega M, Lorenzo O, Egido J. Angiotensin III up-regulates genes involved in kidney damage in mesangial cells and renal interstitial fibroblasts. Kidney Int Suppl 1998; 68: S41-5.
86. Juknevicius I, Segal Y, Kren S, Lee R, Hostetter TH. Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol Renal Physiol 2004; 286(6): F1059-62.
87. Sun Y, Zhang J, Zhang JQ, Ramires FJ. Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats. Hypertension 2000; 35(5): 1078-84.
88. Huang W, Xu C, Kahng KW, Noble NA, Border WA, Huang Y. Aldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells. Am J Physiol Renal Physiol 2008; 294(6): F1287-95.
89. Han JS, Choi BS, Yang CW, Kim YS. Aldosterone-induced TGFbeta1 expression is regulated by mitogen-activated protein kinases and activator protein-1 in mesangial cells. J Korean Med Sci 2009; 24 Suppl: S195-203.
90. Usher MG, Duan SZ, Ivaschenko CY, et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 2010; 120(9): 3350-64.
91. Herrada AA, Contreras FJ, Marini NP, et al. Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. J Immunol 2010; 184(1): 191-202.
92. Houlihan CA, Akdeniz A, Tsalamandris C, Cooper ME, Jerums G, Gilbert RE. Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care 2002; 25(6): 1072-7.
93. Antonipillai I, Le TH, Soceneantu L, Horton R. Transforming growth factor-beta is a renin secretagogue at picomolar concentrations. Am J Physiol 1993; 265(4 Pt 2): F537-41.
94. Brezniceanu ML, Wei CC, Zhang SL, et al. Transforming growth factor-beta 1 stimulates angiotensinogen gene expression in kidney proximal tubular cells. Kidney Int 2006; 69(11): 1977-85.
95. Ellmers LJ, Scott NJ, Medicherla S, et al. Transforming growth factor-beta blockade down-regulates the renin-angiotensin system and modifies cardiac remodeling after myocardial infarction. Endocrinology 2008; 149(11): 5828-34.
96. Petrov VV, Fagard RH, Lijnen PJ. Transforming growth factorbeta(1) induces angiotensin-converting enzyme synthesis in rat cardiac fibroblasts during their differentiation to myofibroblasts. J Renin Angiotensin Aldosterone Syst 2000; 1(4): 342-52.
97. Renzoni EA, Abraham DJ, Howat S, et al. Gene expression profiling reveals novel TGFbeta targets in adult lung fibroblasts. Respir Res 2004; 5: 24.
98. Naaman-Reperant E, Hales DB, Durand P. Effect of transforming growth factor beta-1 on the cholesterol side-chain cleavage system in the adrenal gland of sheep fetuses and newborns. Endocrinology 1996; 137(3): 886-92.
99. Brand C, Cherradi N, Defaye G, et al. Transforming growth factor beta1 decreases cholesterol supply to mitochondria via repression of steroidogenic acute regulatory protein expression. J Biol Chem 1998; 273(11): 6410-6.
100. Le Roy C, Li JY, Stocco DM, Langlois D, Saez JM. Regulation by adrenocorticotropin (ACTH), angiotensin II, transforming growth factor-beta, and insulin-like growth factor I of bovine adrenal cell steroidogenic capacity and expression of ACTH receptor, steroidogenic acute regulatory protein, cytochrome P450c17, and 3beta-hydroxysteroid dehydrogenase. Endocrinology 2000; 141(5): 1599-607.
101. Lehmann TP, Biernacka-Lukanty JM, Trzeciak WH, Li JY. Steroidogenic factor 1 gene transcription is inhibited by transforming growth factor beta. Endocr Res 2005; 31(2): 71-9.
102. Luo X, Ikeda Y, Parker KL. A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell 1994; 77(4): 481-90.
103. Lala DS, Rice DA, Parker KL. Steroidogenic factor I, a key regulator of steroidogenic enzyme expression, is the mouse homolog of fushi tarazu-factor I. Mol Endocrinol 1992; 6(8): 1249-58.
104. Rice DA, Mouw AR, Bogerd AM, Parker KL. A shared promoter element regulates the expression of three steroidogenic enzymes. Mol Endocrinol 1991; 5(10): 1552-61.
105. Ragazzon B, Cazabat L, Rizk-Rabin M, et al. Inactivation of the Carney complex gene 1 (protein kinase A regulatory subunit 1A) inhibits SMAD3 expression and TGF beta-stimulated apoptosis in adrenocortical cells. Cancer Res 2009; 69(18): 7278-84.
106. Parviainen H, Schrade A, Kiiveri S, et al. Expression of Wnt and TGF-beta pathway components and key adrenal transcription factors in adrenocortical tumors: association to carcinoma aggressiveness. Pathol Res Pract 2013; 209(8): 503-9.
107. Boccuzzi A, Terzolo M, Cappia S, et al. Different immunohistochemical patterns of TGF-beta1 expression in benign and malignant adrenocortical tumours. Clin Endocrinol (Oxf) 1999; 50(6): 801-8.
108. Frank J, Roux J, Kawakatsu H, et al. Transforming growth factorbeta1 decreases expression of the epithelial sodium channel alphaENaC and alveolar epithelial vectorial sodium and fluid transport via an ERK1/2-dependent mechanism. J Biol Chem 2003; 278(45): 43939-50.
109. Husted RF, Matsushita K, Stokes JB. Induction of resistance to mineralocorticoid hormone in cultured inner medullary collecting duct cells by TGF-beta 1. Am J Physiol 1994; 267(5 Pt 2): F767-75.
110. Husted RF, Sigmund RD, Stokes JB. Mechanisms of inactivation of the action of aldosterone on collecting duct by TGF-beta. Am J Physiol Renal Physiol 2000; 278(3): F425-33.
111. Peters DM, Vadasz I, Wujak L, et al. TGF-beta directs trafficking of the epithelial sodium channel ENaC which has implications for ion and fluid transport in acute lung injury. Proc Natl Acad Sci U S A 2014; 111(3): E374-83.
112. Chen LM, Zhang X, Chai KX. Regulation of prostasin expression and function in the prostate. Prostate 2004; 59(1): 1-12.
113. Wakida N, Kitamura K, Tuyen DG, et al. Inhibition of prostasininduced ENaC activities by PN-1 and regulation of PN-1 expression by TGF-beta1 and aldosterone. Kidney Int 2006; 70(8): 1432-8.
114. Chang CT, Hung CC, Chen YC, et al. Transforming growth factorbeta1 decreases epithelial sodium channel functionality in renal collecting duct cells via a Smad4-dependent pathway. Nephrol Dial Transplant 2008; 23(4): 1126-34.
115. Salyer SA, Parks J, Barati MT, et al. Aldosterone regulates Na(+), K(+) ATPase activity in human renal proximal tubule cells through mineralocorticoid receptor. Biochim Biophys Acta 2013; 1833(10): 2143-52.
116. Drumm K, Kress TR, Gassner B, Krug AW, Gekle M. Aldosterone stimulates activity and surface expression of NHE3 in human primary proximal tubule epithelial cells (RPTEC). Cell Physiol Biochem 2006; 17(1-2): 21-8.
117. Nowak G, Schnellmann RG. Autocrine production and TGF-beta 1-mediated effects on metabolism and viability in renal cells. Am J Physiol 1996; 271(3 Pt 2): F689-97.
118. Tang MJ, Wang YK, Lin HH. Butyrate and TGF-beta downregulate Na,K-ATPase expression in cultured proximal tubule cells. Biochem Biophys Res Commun 1995; 215(1): 57-66.
119. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43(2): 109-42.
120. Huang PL, Huang Z, Mashimo H, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377(6546): 239-42.
121. Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC, Moskowitz MA. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science 1994; 265(5180): 1883-5.
122. MacMicking JD, Nathan C, Hom G, et al. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 1995; 81(4): 641-50.
123. Inoue N, Venema RC, Sayegh HS, Ohara Y, Murphy TJ, Harrison DG. Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-beta 1. Arterioscler Thromb Vasc Biol 1995; 15(8): 1255-61.
124. Saura M, Zaragoza C, Cao W, et al. Smad2 mediates transforming growth factor-beta induction of endothelial nitric oxide synthase expression. Circ Res 2002; 91(9): 806-13.
125. Ying WZ, Aaron KJ, Sanders PW. Transforming growth factorbeta regulates endothelial function during high salt intake in rats. Hypertension 2013; 62(5): 951-6.
126. Forstermann U, Schmidt HH, Kohlhaas KL, Murad F. Induced RAW 264.7 macrophages express soluble and particulate nitric oxide synthase: inhibition by transforming growth factor-beta. Eur J Pharmacol 1992; 225(2): 161-5.
127. Junquero DC, Scott-Burden T, Schini VB, Vanhoutte PM. Inhibition of cytokine-induced nitric oxide production by transforming growth factor-beta 1 in human smooth muscle cells. J Physiol 1992; 454: 451-65.
128. Vodovotz Y, Bogdan C, Paik J, Xie QW, Nathan C. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta. J Exp Med 1993; 178(2): 605-13.
129. Vodovotz Y, Geiser AG, Chesler L, et al. Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor beta 1 null mouse. J Exp Med 1996; 183(5): 2337-42.
130. Vodovotz Y, Kopp JB, Takeguchi H, et al. Increased mortality, blunted production of nitric oxide, and increased production of TNF-alpha in endotoxemic TGF-beta1 transgenic mice. J Leukoc Biol 1998; 63(1): 31-9.
131. Lastres P, Letamendia A, Zhang H, et al. Endoglin modulates cellular responses to TGF-beta 1. J Cell Biol 1996; 133(5): 1109-21.
132. Pece-Barbara N, Cymerman U, Vera S, Marchuk DA, Letarte M. Expression analysis of four endoglin missense mutations suggests that haploinsufficiency is the predominant mechanism for hereditary hemorrhagic telangiectasia type 1. Hum Mol Genet 1999; 8(12): 2171-81.
133. Lebrin F, Goumans MJ, Jonker L, et al. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 2004; 23(20): 4018-28.
134. Blanco FJ, Santibanez JF, Guerrero-Esteo M, Langa C, Vary CP, Bernabeu C. Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J Cell Physiol 2005; 204(2): 574-84.
135. Guerrero-Esteo M, Sanchez-Elsner T, Letamendia A, Bernabeu C. Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J Biol Chem 2002; 277(32): 29197-209.
136. Merta M, Reiterova J, Tesar V, Stekrova J, Viklicky O. Influence of the endothelial nitric oxide synthase polymorphism on the progression of autosomal dominant polycystic kidney disease and IgA nephropathy. Ren Fail 2002; 24(5): 585-93.
137. Jerkic M, Rivas-Elena JV, Prieto M, et al. Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J 2004; 18(3): 609-11.
138. Toporsian M, Gros R, Kabir MG, et al. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res 2005; 96(6): 684-92.
139. Mutoh A, Isshiki M, Fujita T. Aldosterone enhances ligandstimulated nitric oxide production in endothelial cells. Hypertens Res 2008; 31(9): 1811-20.
140. Boo YC, Sorescu G, Boyd N, et al. Shear stress stimulates phosphorylation of endothelial nitric-oxide synthase at Ser1179 by Akt-independent mechanisms: role of protein kinase A. J Biol Chem 2002; 277(5): 3388-96.
141. Roczniak A, Zimpelmann J, Burns KD. Effect of dietary salt on neuronal nitric oxide synthase in the inner medullary collecting duct. Am J Physiol 1998; 275(1 Pt 2): F46-54.
142. Althaus M, Pichl A, Clauss WG, Seeger W, Fronius M, Morty RE. Nitric oxide inhibits highly selective sodium channels and the Na+/K+-ATPase in H441 cells. Am J Respir Cell Mol Biol 2011; 44(1): 53-65.
143. Hyndman KA, Boesen EI, Elmarakby AA, et al. Renal collecting duct NOS1 maintains fluid-electrolyte homeostasis and blood pressure. Hypertension 2013; 62(1): 91-8.
144. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332(6163): 411-5.
145. Shichiri M, Hirata Y, Nakajima T, et al. Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines. J Clin Invest 1991; 87(5): 1867-71.
146. Shichiri M, Kato H, Marumo F, Hirata Y. Endothelin-1 as an autocrine/paracrine apoptosis survival factor for endothelial cells. Hypertension 1997; 30(5): 1198-203.
147. Reid K, Turnley AM, Maxwell GD, et al. Multiple roles for endothelin in melanocyte development: regulation of progenitor number and stimulation of differentiation. Development 1996; 122(12): 3911-9.
148. Achmad TH, Rao GS. Chemotaxis of human blood monocytes toward endothelin-1 and the influence of calcium channel blockers. Biochem Biophys Res Commun 1992; 189(2): 994-1000.
149. Ishida K, Takeshige K, Minakami S. Endothelin-1 enhances superoxide generation of human neutrophils stimulated by the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine. Biochem Biophys Res Commun 1990; 173(2): 496-500.
150. Kasperk CH, Borcsok I, Schairer HU, et al. Endothelin-1 is a potent regulator of human bone cell metabolism in vitro. Calcif Tissue Int 1997; 60(4): 368-74.
151. Bhattacharya I, Ullrich A. Endothelin-1 inhibits adipogenesis: role of phosphorylation of Akt and ERK1/2. FEBS Lett 2006; 580(24): 5765-71.
152. Takagi H, Reinach PS, Yoshimura N, Honda Y. Endothelin-1 promotes corneal epithelial wound healing in rabbits. Curr Eye Res 1994; 13(8): 625-8.
153. Xu D, Emoto N, Giaid A, et al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994; 78(3): 473-85.
154. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348(6303): 730-2.
155. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990; 348(6303): 732-5.
156. Wang Y, Simonson MS. Voltage-insensitive Ca2+ channels and Ca2+/calmodulin-dependent protein kinases propagate signals from endothelin-1 receptors to the c-fos promoter. Mol Cell Biol 1996; 16(10): 5915-23.
157. Schramek H, Wang Y, Konieczkowski M, Simonson MS, Dunn MJ. Endothelin-1 stimulates cytosolic phospholipase A2 activity and gene expression in rat glomerular mesangial cells. Kidney Int 1994; 46(6): 1644-52.
158. Ujiie K, Terada Y, Nonoguchi H, Shinohara M, Tomita K, Marumo F. Messenger RNA expression and synthesis of endothelin-1 along rat nephron segments. J Clin Invest 1992; 90(3): 1043-8.
159. Chen M, Todd-Turla K, Wang WH, et al. Endothelin-1 mRNA in glomerular and epithelial cells of kidney. Am J Physiol 1993; 265(4 Pt 2): F542-50.
160. Terada Y, Tomita K, Nonoguchi H, Marumo F. Different localization of two types of endothelin receptor mRNA in microdissected rat nephron segments using reverse transcription and polymerase chain reaction assay. J Clin Invest 1992; 90(1): 107-12.
161. Kohan DE, Padilla E, Hughes AK. Endothelin B receptor mediates ET-1 effects on cAMP and PGE2 accumulation in rat IMCD. Am J Physiol 1993; 265(5 Pt 2): F670-6.
162. Bugaj V, Pochynyuk O, Mironova E, Vandewalle A, Medina JL, Stockand JD. Regulation of the epithelial Na+ channel by endothelin-1 in rat collecting duct. Am J Physiol Renal Physiol 2008; 295(4): F1063-70.
163. Lynch IJ, Welch AK, Kohan DE, Cain BD, Wingo CS. Endothelin- 1 inhibits sodium reabsorption by ET(A) and ET(B) receptors in the mouse cortical collecting duct. Am J Physiol Renal Physiol 2013; 305(4): F568-73.
164. Gilmore ES, Stutts MJ, Milgram SL. SRC family kinases mediate epithelial Na+ channel inhibition by endothelin. J Biol Chem 2001; 276(45): 42610-7.
165. Pavlov TS, Chahdi A, Ilatovskaya DV, et al. Endothelin-1 inhibits the epithelial Na+ channel through betaPix/14-3-3/Nedd4-2. J Am Soc Nephrol 2010; 21(5): 833-43.
166. Hyndman KA, MacDonell AH, Pollock JS. Extracellular signalregulated kinases 1/2 signaling pathways are not involved in endothelin regulation of mouse inner medullary collecting duct nitric oxide production. Life Sci 2012; 91(13-14): 578-82.
167. Kurihara Y, Kurihara H, Suzuki H, et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994; 368(6473): 703-10.
168. Ahn D, Ge Y, Stricklett PK, et al. Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest 2004; 114(4): 504-511.
169. Ge Y, Bagnall A, Stricklett PK, et al. Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Renal Physiol 2006; 291(6): F1274-80.
170. Bugaj V, Mironova E, Kohan DE, Stockand JD. Collecting ductspecific endothelin B receptor knockout increases ENaC activity. Am J Physiol Cell Physiol 2012; 302(1): C188-94.
171. Schneider MP, Ge Y, Pollock DM, Pollock JS, Kohan DE. Collecting duct-derived endothelin regulates arterial pressure and Na excretion via nitric oxide. Hypertension 2008; 51(6): 1605-10.
172. Kurihara H, Yoshizumi M, Sugiyama T, et al. Transforming growth factor-beta stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophys Res Commun 1989; 159(3): 1435-40.
173. Zoja C, Orisio S, Perico N, et al. Constitutive expression of endothelin gene in cultured human mesangial cells and its modulation by transforming growth factor-beta, thrombin, and a thromboxane A2 analogue. Lab Invest 1991; 64(1): 16-20.
174. Resink TJ, Hahn AW, Scott-Burden T, Powell J, Weber E, Buhler FR. Inducible endothelin mRNA expression and peptide secretion in cultured human vascular smooth muscle cells. Biochem Biophys Res Commun 1990; 168(3): 1303-10.
175. Horie M, Uchida S, Yanagisawa M, Matsushita Y, Kurokawa K, Ogata E. Mechanisms of endothelin-1 mRNA and peptides induction by TGF-beta and TPA in MDCK cells. J Cardiovasc Pharmacol 1991; 17 Suppl 7: S222-5.
176. Rodriguez-Pascual F, Redondo-Horcajo M, Lamas S. Functional cooperation between Smad proteins and activator protein-1 regulates transforming growth factor-beta-mediated induction of endothelin-1 expression. Circ Res 2003; 92(12): 1288-95.
177. Lee SD, Lee DS, Chun YG, et al. Transforming growth factorbeta1 induces endothelin-1 in a bovine pulmonary artery endothelial cell line and rat lungs via cAMP. Pulm Pharmacol Ther 2000; 13(6): 257-65.
178. Schnermann JB, Zhu XL, Shu X, et al. Regulation of endothelin production and secretion in cultured collecting duct cells by endogenous transforming growth factor-beta. Endocrinology 1996; 137(11): 5000-8.
179. Iwai J, Dahl LK, Knudsen KD. Genetic influence on the reninangiotensin system: low renin activities in hypertension-prone rats. Circ Res 1973; 32(6): 678-84.
180. Rapp JP, Tan SY, Margolius HS. Plasma mineralocorticoids, plasma renin, and urinary kallikrein in salt-sensitive and saltresistant rats. Endocr Res Commun 1978; 5(1): 35-41.
181. Tew SR, Vasieva O, Peffers MJ, Clegg PD. Post-transcriptional gene regulation following exposure of osteoarthritic human articular chondrocytes to hyperosmotic conditions. Osteoarthritis Cartilage 2011; 19(8): 1036-46.
182. Tamaki K, Okuda S, Nakayama M, Yanagida T, Fujishima M. Transforming growth factor-beta 1 in hypertensive renal injury in Dahl salt-sensitive rats. J Am Soc Nephrol 1996; 7(12): 2578-89.
183. Murphy SR, Dahly-Vernon AJ, Dunn KM, et al. Renoprotective effects of anti-TGF-beta antibody and antihypertensive therapies in Dahl S rats. Am J Physiol Regul Integr Comp Physiol 2012; 303(1): R57-69.
184. Chen CC, Geurts AM, Jacob HJ, Fan F, Roman RJ. Heterozygous knockout of transforming growth factor-beta1 protects Dahl S rats against high salt-induced renal injury. Physiol Genomics 2013; 45(3): 110-8.
185. Ying WZ, Sanders PW. Dietary salt modulates renal production of transforming growth factor-beta in rats. Am J Physiol 1998; 274(4 Pt 2): F635-41.
186. Zheng Y, Liu ZQ, Ye T, et al. Effects of high salt diet on blood pressure, renal morphology and osteopontin expression in Sprague- Dawley rat with Ang II-induced renal injury. Di Yi Jun Yi Da Xue Xue Bao 2005; 25(7): 827-32.
187. Habibi J, Hayden MR, Ferrario CM, Sowers JR, Whaley-Connell AT. Salt Loading Promotes Kidney Injury via Fibrosis in Young Female Ren2 Rats. Cardiorenal Med 2014; 4(1): 43-52.
188. Whaley-Connell AT, Habibi J, Aroor A, et al. Salt loading exacerbates diastolic dysfunction and cardiac remodeling in young female Ren2 rats. Metabolism 2013; 62(12): 1761-71.
189. Ying WZ, Aaron K, Wang PX, Sanders PW. Potassium inhibits dietary salt-induced transforming growth factor-beta production. Hypertension 2009; 54(5): 1159-63.
190. Ying WZ, Aaron K, Sanders PW. Mechanism of dietary saltmediated increase in intravascular production of TGF-beta1. Am J Physiol Renal Physiol 2008; 295(2): F406-14.
191. Avraham H, Park SY, Schinkmann K, Avraham S. RAFTK/Pyk2- mediated cellular signalling. Cell Signal 2000; 12(3): 123-33.
192. Onozato ML, Tojo A, Kobayashi N, Goto A, Matsuoka H, Fujita T. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. Nephrol Dial Transplant 2007; 22(5): 1314-22.